Publication Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Oncology Briefings Vol. 6, No. 7

A Summary of Selected Presentations From the Seventh International Kidney Cancer Symposium
September 26-27, 2008; Chicago, IL

Release Date: November 17, 2008
Expiration Date: November 17, 2009

Publication Overview

Authors

Medical writer:
Aarati Ranganathan, PhD; Reviewed by:
Ronald Bukowski, MD

Overview and Purpose

In 2008, an estimated 54,390 new cases of renal cell carcinoma (RCC) are expected to be diagnosed in the United States, with approximately 13,000 resultant deaths. Nearly 40% of these patients will be diagnosed at an advanced disease stage or will progress to metastatic disease. The insertion of targeted agents into the therapeutic arena has replaced standard cytokine therapy in advanced RCC, with inhibitors of growth factor signaling pathways, such as antiangiogenic agents, that have significantly enhanced clinical benefit compared to cytokines. Two small-molecule tyrosine kinase inhibitors of vascular endothelial growth factor receptors (VEGFRs) and 1 inhibitor of mammalian target of rapamycin (mTOR) have been approved by the US Food and Drug Administration for the treatment of patients with advanced RCC, and several other agents are undergoing clinical development. As the number of available targeted therapies grows, the challenge in treating advanced RCC is devising effective strategies for patients with pretreated disease that had failed VEGF/VEGFR- and/or mTOR-targeted therapies. Several ongoing trials focus on this issue.

The purpose of this activity is to update physicians on recent data on targeted agents in chemotherapy-naive and previously treated patients with advanced RCC, with an emphasis on the efficacy and safety of sequencing targeted agents in subsequent lines of therapy.

Target Audience

This activity is intended for medical oncologists involved in the care of patients with renal cell carcinoma. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.

Learning Objectives

Upon completion of this educational activity, you should be able to:

  • Assess the efficacy of agents targeting the VEGF pathway in the treatment of metastatic RCC
  • Describe the adverse event profiles of mTOR inhibitors used in the treatment of RCC
  • Evaluate the impact of mTOR inhibitors on patients with previously treated metastatic RCC

Instructions for Participation

  1. Read the following information before entering the educational activity.
  2. Complete the Pretest.
  3. Study the educational activity.
  4. Complete the CME test.
  5. Answer the evaluation questions.
  6. After successful completion of the CME test and evaluation, you will receive your certificate of credit online.

CME credit will be granted for only 1 form of participation, either online or via the printed publication.

Read all of the conditions in the Activity Terms box below. You must accept the Activity Terms in order to continue:

Disclosure Policy

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

Ararti Ranganathan, PhD
No relevant relationships to disclose

Ronald Bukowski, MD
Research Funding – Pfizer Inc.
Paid Consultant – Antigenics Inc., Bayer Pharmaceuticals Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc., Wyeth Pharmaceuticals
Speaker’s Bureau – Bayer Pharmaceuticals Corporation, Pfizer Inc., Wyeth Pharmaceuticals

PER Editorial Staff
No relevant relationships to disclose

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is located on the title page. Please refer to the full prescribing information for each drug discussed in this online newsletter for FDA-approved dosing, indications, and warnings.

Commercial Support
An educational grant for this activity was provided by Novartis Oncology.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users If you need to upgrade your Web browser, follow one of the links listed below:

Macintosh Users Compatible Web browsers include Firefox (Outside Source) and Apple Safari (Outside Source)

Disclaimer

The views and opinions expressed in this activity are those of the authors and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the authors and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

Privacy Policy

Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949–0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2008 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, Oncology Briefings
Physicians’ Education Resource
 3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367–3456
Fax: (214) 367–3304
E–mail: editor@pergrouplp.com

Download a Print Version of this Publication*

*Print format is for reference only

Educational Grants

An educational grant for this activity was provided by:


  1. Novartis Oncology